Range
80.14 - 81.53
Vol / Avg.
1.2M/896.9K
Div / Yield
-
52 Wk
71.35 - 131.95
Mkt Cap
14.8B
Payout Ratio
-
Open
80.92
P/E
19.32
EPS
0.1
Shares
182.7M
Outstanding
182.7M
Total Float
141.6M
load more
Sector: Health Care.Industry: Biotechnology
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-03
REV
Q1 2021Est.ActualSurprise
EPS-0.1000.090 0.1900
REV446.450M486.030M39.580M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
BMRNBiomarin Pharmaceutical0.47%14.8B

Biomarin Pharmaceutical Frequently Asked Questions

Q

How do I buy Biomarin Pharmaceutical (BMRN) stock?

A

You can purchase shares of Biomarin Pharmaceutical (NASDAQ: BMRN) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Biomarin Pharmaceutical's (BMRN) competitors?

Q

What is the target price for Biomarin Pharmaceutical (BMRN) stock?

A

The latest price target for Biomarin Pharmaceutical (NASDAQ: BMRN) was reported by Morgan Stanley on April 19, 2021. The analyst firm set a price target for 82.00 expecting BMRN to rise to within 12 months (a possible 1.06% upside). 15 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Biomarin Pharmaceutical (BMRN)?

A

The stock price for Biomarin Pharmaceutical (NASDAQ: BMRN) is $81.14 last updated Tue Jun 22 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

Does Biomarin Pharmaceutical (BMRN) pay a dividend?

A

There are no upcoming dividends for Biomarin Pharmaceutical.

Q

When is Biomarin Pharmaceutical (NASDAQ:BMRN) reporting earnings?

A
Biomarin Pharmaceutical’s Q2 earnings are confirmed for after-market on August 3, 2021.
Q

Is Biomarin Pharmaceutical (BMRN) going to split?

A

There is no upcoming split for Biomarin Pharmaceutical.

Q

What sector and industry does Biomarin Pharmaceutical (BMRN) operate in?

A

Biomarin Pharmaceutical is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.